Theratechnologies Announces Completion of Acquisition by Future Pak
1. THTX completes acquisition by CB Biotechnology at US$3.01 per share. 2. Former shareholders may receive an additional US$1.19 contingent value right. 3. Shares to be delisted from TSX and Nasdaq by September 26, 2025. 4. Company will cease as a reporting issuer in Canada. 5. Independent valuator sets CVR market value at US$0.80.